Article

ASCO Mourns Tragic Loss of Board Member Dr. Arti Hurria

Author(s):

Onclive Team

In Partnership With:

ASCO and the entire oncology community are deeply saddened by the loss of colleague, friend, ASCO Board of Directors member, and geriatric oncology leader Arti Hurria, MD, FASCO.

Arti Hurra, MD, FASCO

Arti Hurria, MD, FASCO, ASCO Board of Directors member, geriatric oncology leader

Arti Hurria, MD, FASCO

ASCO and the entire oncology community are deeply saddened by the loss of colleague, friend, ASCO Board of Directors member, and geriatric oncology leader Arti Hurria, MD, FASCO. Dr. Hurria was killed in a traffic accident on November 6, 2018. She was the George Tsai Family Chair in Geriatric Oncology, director of the Center on Cancer and Aging, co-lead of the Cancer Control and Population Sciences Program, vice provost of clinical faculty, a professor in the Department of Medical Oncology & Therapeutics Research, and a medical oncologist at City of Hope.

Related Videos
Alex Herrera, MD
Bertram Yuh, MD, MISM, MSHCPM
Idoroenyi Amanam, MD
Amrita Krishnan, MD, executive medical director, Hematology, director, Judy and Bernard Briskin Multiple Myeloma Center, professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
Idoroenyi Amanam, MD
Saro H. Armenian, DO, MPH
A panel of 3 experts on nasopharyngeal carcinoma
Saro H. Armenian, DO, MPH
Idoroenyi Amanam, MD
A panel of 3 experts on nasopharyngeal carcinoma
Related Content
Maurie Markman, MD, president, Medicine & Science, City of Hope Atlanta, Chicago, and Phoenix
November 20th 2024

Cancer Clinical Trials: A Relevant Need to Clearly Define the Value to Individual Patients

Ravi Salgia, MD, PhD, professor, chair, Department of Medical Oncology & Therapeutics Research, Arthur & Rosalie Kaplan Chair in Medical Oncology & Therapeutics Research, City of Hope
September 2nd 2024

Salgia Summarizes the Benefits of Tepotinib in MET Exon 14–Mutated NSCLC

Maurie Markman, MD, of City of Hope
November 4th 2024

A Call to Action: Determining Optimal Dose, Schedule, and Appropriate Modifications for Antineoplastic Pharmaceutical Agents

Oncology Unplugged
August 21st 2024

Park and Kasi Expand on Perioperative Immunotherapy Updates in CRC

Alex F. Herrera, MD
October 25th 2024

Nivolumab Plus AVD Prolongs PFS vs Brentuximab Vedotin Plus AVD in Advanced-Stage Hodgkin Lymphoma

Saro H. Armenian, DO, MPH, Barron Hilton Chair of Pediatrics, a chair and professor, Department of Pediatrics, director and professor, Division of Outcomes Research/Intervention, Department of Population Sciences, director, Center for Survivorship and Outcomes, Hematologic Malignancies Research Institute, City of Hope
October 2nd 2024

Uncovering and Addressing Unmet Needs in Pediatric Cancer Care